Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of AZD4144 in Participants With Renal Impairment and Healthy Participants
NCT06693765Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AZD4144 (5 cohorts), sponsored by AstraZeneca. Primary endpoints: Observed maximum plasma concentration, Area under the plasma concentration-time curve from time zero extrapolated to infinity and 9 more. Started Nov 2024; status: completed.
02
Drugs
AZD4144
Beyond the preview
Go deeper on NCT06693765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693765.